Nemeckova S, Smahel M, Hainz P, Mackova J, Zurkova K, Gabriel P, Indrova M, Kutinova L
Institute of Hematology and Blood Transfusion, Prague, Czech Republic.
Neoplasma. 2007;54(4):326-33.
Downregulation of MHC class I molecules is believed to be often the cause of tumor immune escape and at the same time it is the major obstacle to T-cell based immunotherapy of tumors. In our experimental model, the C57BL/6 mice bearing tumors induced by TC-1/A9 cells characterized by expression of HPV16 oncogenes and downregulation of H-2b molecules were immunized with highly immunogenic E7GGG.GUS DNA vaccine expressing the fused gene of modified HPV16 E7 (E7GGG) with E.coli beta-glucuronidase (GUS). The DNA vaccine was administered by gene gun on days 7 and 14 after s.c. injection of tumor cells. The tumors in situ were injected with recombinant vaccinia virus MVA expressing the gene for murine granulocyte-macrophage colony-stimulating factor (MVA-GM-CSF). Two doses of the DNA vaccine combined with at least two consecutive local treatments with MVA-GM-CSF were able to inhibit significantly the growth of tumors. We have shown by ELISPOT-IFNgamma that in situ expression of the GM-CSF gene did not enhance the E7 specific systemic Tcell response. We found that local injections of MVA-GM-CSF induced an increase of intratumoral CD3+ T cell counts and that the DNA vaccination resulted in up-regulation of MHC type I molecules on tumor cells in vivo. We suppose that i.t. delivery of MVA-GM-CSF changed the local tumor microenvironment and rendered tumors more attractive and better accessible to effector T cells.
MHC I类分子的下调通常被认为是肿瘤免疫逃逸的原因,同时也是基于T细胞的肿瘤免疫治疗的主要障碍。在我们的实验模型中,用携带由TC-1/A9细胞诱导的肿瘤的C57BL/6小鼠进行免疫,这些肿瘤的特征是HPV16癌基因表达以及H-2b分子下调,使用表达修饰的HPV16 E7(E7GGG)与大肠杆菌β-葡萄糖醛酸酶(GUS)融合基因的高免疫原性E7GGG.GUS DNA疫苗进行免疫。在皮下注射肿瘤细胞后第7天和第14天,通过基因枪给予DNA疫苗。对原位肿瘤注射表达鼠粒细胞-巨噬细胞集落刺激因子基因的重组痘苗病毒MVA(MVA-GM-CSF)。两剂DNA疫苗与至少两次连续的局部MVA-GM-CSF治疗相结合能够显著抑制肿瘤生长。我们通过ELISPOT-IFNγ表明,GM-CSF基因的原位表达并未增强E7特异性全身T细胞反应。我们发现局部注射MVA-GM-CSF可导致肿瘤内CD3 + T细胞计数增加,并且DNA疫苗接种导致体内肿瘤细胞上MHC I类分子上调。我们推测,瘤内递送MVA-GM-CSF改变了局部肿瘤微环境,使肿瘤对效应T细胞更具吸引力且更易被其作用。